Jefferies initiated its coverage of ImmunoGen IMGN with a Buy rating and a price target of $19. On Tuesday, ImmunoGen lost 1.29% of its value to end the day at $12.21. Its shares fell some more in today's pre-market trading, after edging down 0.08% to $12.20.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
